Tigrani V S, Reese D M, Small E J, Presti J C, Carroll P R
Department of Urology, University of California, San Francisco, School of Medicine, 94115, USA.
Urology. 2000 Jan;55(1):36-40. doi: 10.1016/s0090-4295(99)00395-7.
To examine the outcomes of patients with newly diagnosed metastatic renal cell carcinoma (RCC) who underwent initial nephrectomy as a component of therapy, because the role of nephrectomy in the treatment of patients with metastatic RCC is uncertain.
A retrospective review of 63 patients who underwent radical nephrectomy with or without additional surgical procedures in the setting of metastatic RCC was performed. Pretreatment characteristics and the type of surgery were examined as predictors of outcome, and the type of systemic therapy received (if any) and overall survival were determined.
The median patient age was 59 years (range 39 to 79). Thirty-two patients had a single metastatic site, with the most common sites being the lung (n = 33), lymphatics (n = 32), and bone (n = 19). Seventeen patients (27%) also underwent vena cavotomy during surgery. Two patients died perioperatively. Thirty-nine (62%) patients underwent systemic therapy after surgery, and 6 patients (9.5%) were rendered free of disease and elected not to receive systemic treatment. The median survival was 17.8 months.
Primary renal surgery may be beneficial for selected patients with metastatic RCC, and most patients will be able to receive postoperative systemic therapy.
鉴于肾切除术在转移性肾细胞癌(RCC)患者治疗中的作用尚不明确,本研究旨在探讨初诊为转移性RCC且接受了作为治疗一部分的初始肾切除术的患者的治疗结果。
对63例在转移性RCC情况下接受了根治性肾切除术(无论是否进行了额外手术)的患者进行回顾性分析。研究了治疗前特征和手术类型作为预后预测因素,并确定了接受的全身治疗类型(若有)和总生存期。
患者中位年龄为59岁(范围39至79岁)。32例患者有单个转移部位,最常见的部位是肺(n = 33)、淋巴管(n = 32)和骨(n = 19)。17例患者(27%)在手术期间还接受了腔静脉切开术。2例患者在围手术期死亡。39例(62%)患者术后接受了全身治疗,6例(9.5%)患者达到无病状态并选择不接受全身治疗。中位生存期为17.8个月。
对于部分转移性RCC患者,原发性肾脏手术可能有益,且大多数患者能够接受术后全身治疗。